Literature DB >> 22936013

Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in.

V Goede, K Fischer, R Busch, U Jaeger, M-S Dilhuydy, N Wickham, S De Guibert, M Ritgen, A W Langerak, G Bieska, A Engelke, K Humphrey, M Wenger, M Hallek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22936013     DOI： 10.1038/leu.2012.252

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  19 in total

1.  Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion.

Authors:  M Le Garff-Tavernier; L Herbi; C de Romeuf; F Nguyen-Khac; F Davi; A Grelier; M Boudjoghra; K Maloum; S Choquet; R Urbain; V Vieillard; H Merle-Béral
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

Review 2.  Management of chronic lymphocytic leukemia.

Authors:  Paolo Ghia; Michael Hallek
Journal:  Haematologica       Date:  2014-06       Impact factor: 9.941

Review 3.  Complement in monoclonal antibody therapy of cancer.

Authors:  Laura M Rogers; Suresh Veeramani; George J Weiner
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

4.  Synergy: karyotypes and mutations in CLL.

Authors:  Lynne V Abruzzo
Journal:  Blood       Date:  2016-07-21       Impact factor: 22.113

5.  Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.

Authors:  Susan O'Brien; Richard R Furman; Steven E Coutre; Jeff P Sharman; Jan A Burger; Kristie A Blum; Barbara Grant; Donald A Richards; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Raquel Izumi; Ahmed Hamdy; Betty Y Chang; Thorsten Graef; Fong Clow; Joseph J Buggy; Danelle F James; John C Byrd
Journal:  Lancet Oncol       Date:  2013-12-10       Impact factor: 41.316

Review 6.  Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.

Authors:  M A Kharfan-Dabaja; W G Wierda; L J N Cooper
Journal:  Leukemia       Date:  2013-10-25       Impact factor: 11.528

7.  Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.

Authors:  Jennifer R Brown; Susan O'Brien; C Daniel Kingsley; Herbert Eradat; John M Pagel; James Lymp; Jamie Hirata; Thomas J Kipps
Journal:  Blood       Date:  2015-03-13       Impact factor: 22.113

Review 8.  What do we do with chronic lymphocytic leukemia with 17p deletion?

Authors:  L Sellner; S Denzinger; S Dietrich; H Glimm; O Merkel; P Dreger; T Zenz
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

Review 9.  New insights into biology, prognostic factors, and current therapeutic strategies in chronic lymphocytic leukemia.

Authors:  Piotr Smolewski; Magdalena Witkowska; Anna Korycka-Wołowiec
Journal:  ISRN Oncol       Date:  2013-08-22

Review 10.  Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab.

Authors:  Lukáš Smolej
Journal:  Pharmgenomics Pers Med       Date:  2014-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.